Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:2959-2965
Published online before print October 31, 2005, doi: 10.1161/CIRCULATIONAHA.105.584623
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
112/19/2959    most recent
CIRCULATIONAHA.105.584623v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rikitake, Y.
Right arrow Articles by Liao, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rikitake, Y.
Right arrow Articles by Liao, J. K.
Related Collections
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Gene regulation
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression
Right arrow Genetics of cardiovascular disease

(Circulation. 2005;112:2959-2965.)
© 2005 American Heart Association, Inc.


Molecular Cardiology

Decreased Perivascular Fibrosis but Not Cardiac Hypertrophy in ROCK1+/– Haploinsufficient Mice

Yoshiyuki Rikitake, MD, PhD*; Naotsugu Oyama, MD, PhD*; Chao-Yung C. Wang, MD; Kensuke Noma, MD, PhD; Minoru Satoh, MD, PhD; Hyung-Hwan Kim, PhD; James K. Liao, MD

From the Vascular Medicine Research Unit, Brigham and Women’s Hospital and Harvard Medical School, Cambridge, Mass.

Correspondence to James K. Liao, MD, Brigham and Women’s Hospital, 65 Landsdowne St, Room 275, Cambridge, MA 02139. E-mail jliao{at}rics.bwh.harvard.edu

Received June 14, 2005; de novo received August 22, 2005; revision received September 3, 2005; accepted September 7, 2005.

Background— Rho GTPase and its downstream target, Rho-associated kinase (ROCK), have been implicated in diverse cardiovascular diseases such as cardiac hypertrophy. However, pharmacological inhibitors of ROCK are not entirely specific, nor can they discriminate between the ROCK isoforms ROCK1 and ROCK2. To determine the specific role of ROCK1 in the development of cardiac hypertrophy, we generated ROCK1+/– haploinsufficient mice and determined whether cardiac hypertrophy and remodeling are decreased in these mice.

Methods and Results— Litters of ROCK1–/– mice on C57Bl/6 background were markedly underrepresented, suggesting lethality in utero or postnatally. ROCK1+/– mice, however, are viable and fertile with no obvious phenotypic abnormalities. Basal blood pressure, heart rate, and cardiac dimension and function in ROCK1+/– mice were similar to those in wild-type (WT) littermates. Infusion of angiotensin II (400 ng · kg–1 · min–1 for 28 days) or treatment with NG-nitro-L-arginine methyl ester (1 mg/mL in drinking water for 28 days) caused similar increases in systolic blood pressure, left ventricular wall thickness, left ventricular mass, ratio of heart weight to tibial length, and cardiomyocyte size in ROCK1+/– mice and WT littermates. In contrast, perivascular fibrosis in hearts was increased to a lesser extent in ROCK1+/– mice compared with WT littermates. This was associated with decreased expression of transforming growth factor-ß, connective tissue growth factor, and type III collagen. In addition, perivascular fibrosis induced by transaortic constriction or myocardial infarction was decreased in ROCK1+/– mice compared with WT littermates.

Conclusions— These findings indicate ROCK1 is critical for the development of cardiac fibrosis, but not hypertrophy, in response to various pathological conditions and suggest that signaling pathways leading to the hypertrophic and profibrotic response of the heart are distinct.


Key Words: blood pressure • hypertension • hypertrophy • remodeling • angiotensin




This article has been cited by other articles:


Home page
EndocrinologyHome page
H. Ohtsu, S. Higuchi, H. Shirai, K. Eguchi, H. Suzuki, A. Hinoki, E. Brailoiu, A. D. Eckhart, G. D. Frank, and S. Eguchi
Central Role of Gq in the Hypertrophic Signal Transduction of Angiotensin II in Vascular Smooth Muscle Cells
Endocrinology, July 1, 2008; 149(7): 3569 - 3575.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Phrommintikul, L. Tran, A. Kompa, B. Wang, A. Adrahtas, D. Cantwell, D. J. Kelly, and H. Krum
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1804 - H1814.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. L.M. Peters and M. C. Michel
The RhoA/Rho kinase pathway in the myocardium
Cardiovasc Res, July 1, 2007; 75(1): 3 - 4.
[Full Text] [PDF]


Home page
CirculationHome page
M. Satoh, C. M. Matter, H. Ogita, K. Takeshita, C.-Y. Wang, G. W. Dorn II, and J. K. Liao
Inhibition of Apoptosis-Regulated Signaling Kinase-1 and Prevention of Congestive Heart Failure by Estrogen
Circulation, June 26, 2007; 115(25): 3197 - 3204.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P.-Y. Liu, J.-H. Chen, L.-J. Lin, and J. K. Liao
Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome
J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1619 - 1624.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi
Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells
Hypertension, October 1, 2006; 48(4): 534 - 540.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Chang, M. Xie, V. R. Shah, M. D. Schneider, M. L. Entman, L. Wei, and R. J. Schwartz
Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis
PNAS, September 26, 2006; 103(39): 14495 - 14500.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Chrissobolis and C. G. Sobey
Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease
Stroke, August 1, 2006; 37(8): 2174 - 2180.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Satoh, H. Ogita, K. Takeshita, Y. Mukai, D. J. Kwiatkowski, and J. K. Liao
Requirement of Rac1 in the development of cardiac hypertrophy
PNAS, May 9, 2006; 103(19): 7432 - 7437.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Y.-M. Zhang, J. Bo, G. E. Taffet, J. Chang, J. Shi, A. K. Reddy, L. H. Michael, M. D. Schneider, M. L. Entman, R. J. Schwartz, et al.
Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis
FASEB J, May 1, 2006; 20(7): 916 - 925.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. H. Brown, D. P. Del Re, and M. A. Sussman
The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits
Circ. Res., March 31, 2006; 98(6): 730 - 742.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
K. Noma, N. Oyama, and J. K. Liao
Physiological role of ROCKs in the cardiovascular system
Am J Physiol Cell Physiol, March 1, 2006; 290(3): C661 - C668.
[Abstract] [Full Text] [PDF]